Summit Therapeutics Inc.
SMMT
주식 순위
#1708
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
주가
$15.71
시가총액
$12.53B
변동 (1일)
7.35%
변동 (1년)
-25.18%
국가
US
거래 Summit Therapeutics Inc. (SMMT)
카테고리
Healthcare
Summit Therapeutics Inc. (SMMT)의 EPS
June 2026 기준 EPS TTM: $-1.12
Summit Therapeutics Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-1.12입니다. 2023년 말에는 회사의 EPS가 $-0.99였으며, 이는 2022년의 EPS $-0.41와 증가입니다.
Summit Therapeutics Inc.의 EPS 기록 (2004 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-1.12 | 261.29% |
| 2024 | $-0.31 | -68.69% |
| 2023 | $-0.99 | 141.46% |
| 2022 | $-0.41 | -57.29% |
| 2021 | $-0.96 | 26.32% |
| 2020 | $-0.76 | 282.10% |
| 2019 | $-0.20 | -12.46% |
| 2018 | $-0.23 | -58.03% |
| 2017 | $-0.54 | -7.28% |
| 2016 | $-0.58 | -9.84% |
| 2015 | $-0.65 | 15.87% |
| 2014 | $-0.56 | -16.06% |
| 2013 | $-0.67 | 17.30% |
| 2012 | $-0.57 | 86.96% |
| 2011 | $-0.30 | 45.47% |
| 2010 | $-0.21 | -75.78% |
| 2009 | $-0.86 | 3.18% |
| 2008 | $-0.84 | 166.41% |
| 2007 | $-0.31 | 191.63% |
| 2006 | $-0.11 | 1,435.71% |
| 2005 | $-0.01 | 75.00% |
| 2004 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -1,646.43% |
US
|
|
| $-7.98 | 612.50% |
US
|
|
| $-5.29 | 372.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,576.79% |
NL
|
